PRESS RELEASE



Wockhardt Limited

Wockhardt Towers | Bandra Kurla Complex Bandra (East) | Mumbai 400 051 | India T: 91-22-2653 4444 | F: 91-22-2653 4242

W: www.wockhardt.com

Wockhardt takes huge strides towards In-licensing and collaborative agreements

Signs in-licensing deal with UK based Sinclair Pharma

Mumbai, October 9, 2008

Pharmaceutical and biotechnology major Wockhardt Limited has forged an in-licensing agreement with Sinclair Pharma plc of UK to market a range of dermatology and dental products in September 2008. Sinclair Pharma plc is an international speciality pharmaceutical company having subsidiaries in France, Italy, Spain, and Portugal with operations spanning across 82 countries. As per ORG IMS, the Indian dermatology market is worth a whopping Rs. 1,782 crores.

"As a part of our India business strategy, in-licensing is seen as one of our key growth drivers. These in-licensing deals will fulfil our aim of getting niche global products for the benefit of our Indian patients", said Wockhardt chairman Habil Khorakiwala. "We bring to India break through products that have proved their effectiveness in Europe and USA and also strengthen our existing portfolios", he further added.

As per the agreement, Wockhardt will leverage its technological capabilities by manufacturing the formulations in India from bulk imported from Sinclair Pharma. Wockhardt is also in talks with Sinclair on contract manufacturing of the signed products for their European markets and to bring in to India the next phase of dermatology products from the Sinclair stable.

This agreement is a further step towards Wockhardt's strategy of consolidating its position in Dermatology and focus in Dentistry. The 10 year exclusive agreement covers a range of patented and innovative products like;

Papulex – Innovative formulation for acne and is the no. 1 selling product for acne in France

Atopiclair – non steroidal cream for atopic dermatitis

Aloclair – Patented gel for mouth ulcer

Decapinol range – Patented formulation for the treatment of Gingivitis and plaque

Wockhardt Limited is a global pharmaceutical and biotechnology major with an innovative research and development programme. Wockhardt has global footprints including UK, France, Germany, Ireland and USA. Wockhardt employs around 6000 people worldwide belonging to 14 different nationalities.